Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

114.20

+0.33 (0.29%)

as of Jun 18, 2026, 11:15:03 pm Market Open.

161 watching

DON'T BUY

Has a pretty decent pipeline of new products. Current dividend yield is very high. You have to be prepared to ride out the storm of litigations, but could come out nicely. Very risky.

TOP PICK

Up to their necks in litigation. They've lost $30 billion in market cap because an anti-inflammatory has been pulled off the shelf due to heart attack risks. Just lost a $230 million lawsuit which will be reversed on appeal. Only trading at 9 X earnings. Have a ton of cash and generate a ton of free cash flow. 5.5% dividend yield. Very cheap.

DON'T BUY

Pharmaceutical sector did very poorly over the last 2 years, but deceleration in revenue growth has slowed and profitability has started to improve. Look for the strongest perfoming stock in the sector. As Eli Lilly (LLY-N) is performing better, that would be the better of the 2, but would suggest you look at Sanofi-Aventis (SNY-N) which is close to new highs and Teva Pharmaceuticals (TEVA-Q) in generics.

BUY

Pharmaceutical stocks in the US have been absolutely decimated. Dirt cheap. Generates a ton of free cash flow.

BUY

An equally good stock as Pfizer (PFE-N) at these levels. 4.5% yield. Always have good products. Going through a difficult spell right now.

BUY

Great valuation and a good entry point.

DON'T BUY

Would prefer Pfizer (PFE-N) which has a far superior pipeline.

BUY

Big issue has been VIOXX. Very convoluted over the near term as to what will happen. Don't know what the legal issues will be. There could be more bad news from previous users of the drug. Have lots of money. Trades at almost 20% discount to the peer group. Nearly 5% yield. Has room for upside. Won't be an easy road.

WEAK BUY

Thinks it's going to be very tough to legally get this company with VIOXX. They have it as the 11th position in their portfolio. Model price is $38. Prefers Pfizer which has a bigger upside.

WEAK BUY

Feels they should have re-labelled rather than pulling Vioxx so that people would know how to use them properly. A huge number of lawsuits they could face down the road. Didn't grow by acquisition, so their pipeline looks a bit murky. A great company and will be around for a long time.

DON'T BUY

Companies like Pfizer and Merck have been coming apart for quite awhile. Growth rate has gone from 30% to low single digits. When this happens, the P/E has to contract. There are more sellers than buyers. One of the few that is doing better is Schering AG. Growth rate is accelerating and have a good line up of drugs.

DON'T BUY

Facing a large number of large and messy law suits.

WEAK BUY

Mispriced. Expects that down the road Vioxx will come back.

DON'T BUY

A cockroach company with one problem after another coming out of the woodwork.

DON'T BUY

In 2002, 2003 and early 2004 the chart looked like it was going to hold, but then collapsed. A broken down stock. Usually takes a significant amount of time for the news to be absorbed.

Showing 181 to 195 of 252 entries

Most Recent Experts

Stockchase Insights

5i Research

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Merck & Company (MRK)